Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer

被引：0

作者：

Citarella, Fabrizio ^{[1
]}

Russano, Marco ^{[1
]}

Galletti, Alessandro ^{[1
]}

Vincenzi, Bruno ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Santini, Daniele ^{[1
]}

机构：

[1] Univ Campus Biomed Roma, Dept Med Oncol, Via Alvaro Portillo 200, I-00128 Rome, Italy

来源：

CLINICAL LUNG CANCER | 2021年 / 22卷 / 02期

关键词：

D O I：

10.1016/j.cllc.2020.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：137 / 138

页数：2

共 50 条

[11] Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
Levy, Benjamin P.
Rao, Parth
Becker, Daniel J.
Becker, Kevin
ONCOLOGY-NEW YORK, 2016, 30 (07): : 601 - 612
[12] Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option
Passaro, Antonio
de Marinis, Filippo
TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S100 - S102
[13] Project PRIORITY: A Patient-Founded and Patient-Driven Research Partnership on Real-World Data on EGFR-Positive Lung Cancer
Roy, U. Basu
Elkins, I.
Figueras, A.
Kennedy, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S313 - S313
[14] Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group
Sonehara, Kei
Kobayashi, Takashi
Tateishi, Kazunari
Morozumi, Nobutoshi
Yoshiike, Fumiaki
Hachiya, Tsutomu
Ono, Yasushi
Takasuna, Keiichirou
Agatsuma, Toshihiko
Masubuchi, Takeshi
Matsuo, Akemi
Tanaka, Hozumi
Morikawa, Akio
Hanaoka, Masayuki
Koizumi, Tomonobu
THORACIC CANCER, 2019, 10 (05) : 1078 - 1085
[15] Plasma HGF Reduction Is Associated with Better Prognosis in EGFR-Positive Advanced Lung Adenocarcinoma Patients Treated with Afatinib
Arrieta Rodriguez, Oscar
Cruz-Rico, Graciela
Ramirez-Tirado, Laura-Alejandra
Negueb, Jorge
Caballe-Perez, Enrique
Martinez-Alvarez, Ivan
Socca-Chafre, Giovanni
Astudillo, Horacio
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S320 - S321
[16] A heavily pre-treated HIV positive patient with limited treatment options and multiple concomitant diseases treated successfully with raltegravir - the first case in Poland
Szetela, Bartosz
Gasiorowski, Jacek
Zalewska, Malgorzata
HIV & AIDS REVIEW, 2008, 7 (04): : 26 - 28
[17] A macrocyclic kinase inhibitor overcomes the compound mutations that cause the resistance to all approved EGFR inhibitors in EGFR-positive lung cancer
Katayama, Ryohei
Uchibori, Ken
Nishio, Makoto
Fujita, Naoya
CANCER RESEARCH, 2024, 84 (06)
[18] Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Budczies, Jan
Kirchner, Martina
Kluck, Klaus
Kazdal, Daniel
Glade, Julia
Allgaeuer, Michael
Kriegsmann, Mark
Heussel, Claus-Peter
Herth, Felix J.
Winter, Hauke
Meister, Michael
Muley, Thomas
Goldmann, Torsten
Froehling, Stefan
Wermke, Martin
Waller, Cornelius F.
Tufman, Amanda
Reck, Martin
Peters, Solange
Schirmacher, Peter
Thomas, Michael
Christopoulos, Petros
Stenzinger, Albrecht
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (02) : 251 - 265
[19] NANOBODY CDR3 PEPTIDOMIMETICS AS EGFR-POSITIVE CANCER DIAGNOSTICS
Betti, C.
Krummenacher, S.
Martin, C.
Boeglin, J.
Xavier, C.
Devoogdt, N.
Caveliers, V.
Ballet, S.
JOURNAL OF PEPTIDE SCIENCE, 2016, 22 : S214 - S214
[20] Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies
Martina Kirchner
Klaus Kluck
Daniel Kazdal
Julia Glade
Michael Allgäuer
Mark Kriegsmann
Claus-Peter Heußel
Felix J. Herth
Hauke Winter
Michael Meister
Thomas Muley
Torsten Goldmann
Stefan Fröhling
Martin Wermke
Cornelius F. Waller
Amanda Tufman
Martin Reck
Solange Peters
Peter Schirmacher
Michael Thomas
Petros Christopoulos
Albrecht Stenzinger
Cancer Immunology, Immunotherapy, 2022, 71 : 251 - 265

← 1 2 3 4 5 →